Recent events
Recent events tied to this brand in public sources.
Back to profile13 entries
2021
Natera announces follow-on offering pricing
Natera announced pricing for an underwritten public offering of 4,500,000 common shares at $113.00 per share. Closing was expected on July 26, 2021, subject to customary conditions.
2021
Guardant Health sues Natera over alleged advertising claims
Guardant Health sued Natera, alleging that Natera ran a campaign of false and misleading advertising concerning Guardant's Reveal cancer assay and made unfounded comparisons with its own product. These are allegations in the lawsuit.
2021
Natera sues Inivata over alleged patent infringement
Natera filed a lawsuit against Inivata Ltd. and its wholly owned subsidiary, alleging infringement of two U.S. patents. Natera seeks injunctive relief and monetary damages; the allegations are claims in the lawsuit, not a stated court determination.
2020
Natera appoints Monica Bertagnolli to its board
Natera announced that it appointed Dr. Monica Bertagnolli to its board of directors.
2020
Natera announces pricing of follow-on offering
Natera announced pricing for an underwritten public offering of 4,166,666 common shares at $60.00 per share. The closing was expected on September 15, subject to customary conditions.
2020
Natera and Mass General Cancer Center announce clinical-trial collaboration
Natera announced a collaborative agreement with Mass General Cancer Center of Massachusetts General Hospital related to the LEADER multi-center randomized clinical trial in early-stage breast cancer, which will use Natera’s Signatera test.
2020
Natera files patent suit against Progenity
Natera filed suit against Progenity in the U.S. District Court for the Western District of Texas, alleging that Progenity's use and sale of its non-invasive prenatal test infringed six patents. Natera sought injunctive relief and monetary damages; the source reports allegations, not a court determination.
2020
Natera launches background cfDNA quantification technique for Prospera
Natera announced the launch of a technique that quantifies background cfDNA to enhance results from its Prospera transplant rejection assessment test.
2020
Natera withdraws 2020 financial guidance
Natera withdrew its financial guidance for fiscal year 2020, citing the dynamic situation and ongoing disruptions from COVID-19 and saying it could not predict the outbreak's impact on operating results.
2020
Natera sues ArcherDX over patent infringement
Natera filed suit against ArcherDX in the U.S. District Court of Delaware. Natera's complaint alleges that ArcherDX's sale and use of certain cell-free DNA-based oncology products infringes Natera's patent; the allegation is not presented as a court determination.
2020
Natera files patent infringement suit against CareDx
Natera said it filed suit against CareDx alleging infringement of Natera's U.S. Patent 10,526,658. The article reports the allegation, not a court determination.
2019
Natera enters partnership with Foundation Medicine
Natera reported that it entered a partnership with Foundation Medicine to develop and commercialize personalized circulating tumor DNA monitoring assays.
2019
Natera reports third-quarter 2019 results
Natera reported third-quarter 2019 financial results, including total revenue of $77.9 million, up 19% from the same quarter in 2018.